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Sir,
In the recently published review, ‘Aromatase inhibition in the
treatment of advanced breast cancer: is there a relationship
between potency and clinical efficacy?’ (Sainsbury, 2004), the
author claims that differences in the potency of aromatase
inhibition and oestrogen suppression among the modern aroma-
tase inhibitors do not translate into differences in efficacy benefits.
The clinical trial results listed within the article, however,
contradict the author’s conclusion. Furthermore, some of the more
general statements within this review must be challenged.
Dr Sainsbury claims to see no efficacy differences between
letrozole and anastrozole, despite the former being associated with
higher potency in aromatase inhibition and oestrogen suppression
(Geisler et al, 2002). The author makes a number of indirect
comparisons of different trials to support his point: the first-line
advanced breast cancer trials of anastrozole or letrozole vs tamoxifen
demonstrated ‘anastrozole to be at least as effective as tamoxifen’
(Bonneterre et al, 2001; Nabholtz et al, 2003), whereas ‘letrozole was
found to be superior to tamoxifen’ in all end points including a
prospectively planned survival analysis at 1- and 2-year follow-up,
which is not mentioned in this review (Mouridsen et al, 2003).
In a head-to-head comparison of anastrozole vs letrozole in
second-line advanced breast cancer, results were comparable in all
end points except overall response rate (ORR), which was more
than 50% higher in patients treated with letrozole (Rose et al,
2003). While ORR was a secondary rather than primary end point
of the trial, the higher likelihood of responding to endocrine
therapy is inarguably highly relevant for women with advanced
stage breast cancer, as response implies both personal relief as well
as delay of more aggressive, usually cytotoxic, therapies.
Dr Sainsbury uses a subgroup analysis to challenge the results of
this 713-patient trial, citing a significant superiority for letrozole
only in the group of patients with undetermined hormone receptor
status. Letrozole response rates in this group of patients were
similar to those in the overall trial collective, not surprisingly so, as
at least two-thirds of these patients are likely to bear oestrogen
receptor (ER)- and/or progesterone receptor (PgR)-positive
tumours. In view of the size of the ER/PgR-unknown subgroup
(n¼340), the well-balanced demographics in the two trial arms
overall, and the high chance of a tumour of undetermined hormone
receptor status being positive renders statistical imbalance of ER/
PgR status in favour of letrozole, a very unlikely explanation for the
2.5-fold increased response rate achieved with letrozole.
In fact, the high efficacy of letrozole in ER/PgR-unknown tumours
in this second-line study is consistent with results of the phase III
first-line comparison of letrozole vs tamoxifen, in which the
superiority of letrozole over tamoxifen was consistent among both
ER/PgR-positive and -unknown patients – in contrast to the
anastrozole trials that demonstrated superiority only in the ER/
PgR-positive subgroup. While hard to explain, it seems that while
letrozole may be effectively used in both hormone receptor-positive
and -unknown patients, the efficacy of anastrozole appears limited
to only those patients with a distinct expression of ER/PgR.
The efficacy of an endocrine agent in ER/PgR-unknown patients
remains clinically relevant, as even today there is a pool of patients
with advanced breast cancer of undetermined ER/PgR status.
While Dr Sainsbury maintains that ‘ythey [AIs] are used in this
[hormone receptor-positive] group of patients’, this is, in fact, not
entirely true for advanced breast cancer: endocrine therapy is still
widely recommended for these women with receptor-unknown
advanced breast cancer, based on the fact that the majority will be
endocrine responsive and a response to endocrine therapy would
delay chemotherapy (National Cancer Institute, 2004).
Within the summary of this review, the author introduces the
notion that while the degree of oestrogen suppression beyond a
certain threshold does not translate into increased antitumour
efficacy, it might well result in different toxicity profiles. This
statement is purely speculative and is not supported by any data
available so far. We are not aware of any research demonstrating
that endocrine-sensitive normal tissues, such as bone, would
be more sensitive to small changes in oestrogen levels than
breast cancer cells, which are well recognised for their ability to
develop a pronounced hypersensitivity to small levels of oestrogen
(Masamura et al, 1995). Using bone metabolism as an example, we
may point out that the less potent aromatase inhibitor anastrozole
has been associated with a marked increase in fracture rates when
used in early breast cancer (Baum et al, 2002, 2003), whereas
letrozole has not (Goss et al, 2003).
The author of this letter is a consultant to Novartis Oncology. It
would seem advisable that future reviews of the kind published by
Dr Sainsbury include disclosure of the author’s potential conflicts
of interest as well. Published online 15 March 2005
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